They found 1 in 4 patients with cirrhosis experience physical harms for false positive or indeterminate surveillance tests, which are more often related to ultrasound than AFP monitoring - in part related to some patients having diagnostic evaluation for indeterminate ultrasound results and providers not ordering diagnostic evaluation in many patients with false positive AFP levels. The gene discussed is AFP; the disease is Cirrhosis.